I'm LongbridgeAI, I can summarize articles.Deutsche Bank Aktiengesellschaft has downgraded Merck KGaA (OTCMKTS:MKKGY) from a "buy" to a "hold" rating. The stock opened at $29.88, with a one-year low of $24.32 and a high of $31.00. Merck KGaA reported $0.81 earnings per share for the last quarter, exceeding estimates. The company has a market cap of $19.31 billion and a PE ratio of 11.90. Analysts predict an EPS of 1.87 for the current fiscal year.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) was downgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating in a report released on Tuesday.
Merck KGaA Price Performance
MKKGY opened at $29.88 on Tuesday. Merck KGaA has a one year low of $24.32 and a one year high of $31.00. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.97 and a current ratio of 1.49. The company has a market capitalization of $19.31 billion, a PE ratio of 11.90, a P/E/G ratio of 6.05 and a beta of 0.96. The stock's fifty day moving average is $28.80 and its 200-day moving average is $27.02.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.27. The business had revenue of $6.17 billion during the quarter, compared to analyst estimates of $6.08 billion. Merck KGaA had a return on equity of 10.07% and a net margin of 13.92%. On average, equities analysts predict that Merck KGaA will post 1.87 EPS for the current fiscal year.
Merck KGaA Company Profile
(Get Free Report)Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck's Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
Featured Articles
- Five stocks we like better than Merck KGaA
- The day the gold market broke
- Forget AI, This Will Be the Next Big Tech Breakthrough
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold’s getting scarce.
- ALERT: Drop these 5 stocks before the market opens tomorrow!
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Merck KGaA Right Now?
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here